Fan Emily Yang
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Psoriasis: Treatment and Pathogenesis, Allergic Rhinitis and Sensitization, Food Allergy and Anaphylaxis Research
Most-Cited Works
- → Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis(2020)270 cited
- → Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis(2018)118 cited
- → Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)(2022)72 cited
- → Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials(2022)53 cited
- → Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial(2021)53 cited
- → Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis(2016)53 cited
- Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis.(2018)
- → Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials(2024)16 cited
- → Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)(2024)6 cited
- → 012 Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis(2018)5 cited